gp100209-2M Peptide Immunization of Human Lymphocyte Antigen-A2+ Stage I-III Melanoma Patients Induces Significant Increase in Antigen-Specific Effector and Long-Term Memory CD8+ T Cells

Clinical Cancer Research

Volumn 10, Issue 2, 2004, Pages 668-680

  Walker, Edwin B ^a   Haley, Daniel ^a   Miller, William ^a   Floyd, Kevin ^a   Wisner, Ketura P ^a   Sanjuan, Nelson ^a   Maecker, Holden ^c   Romero, Pedro ^d   Hu, Hong Ming ^a   Alvord, W Gregory ^e   Smith II, John W ^a   Fox, Bernard A ^a,b   Urba, Walter J ^a  

^a EARLE A CHILES RESEARCH INSTITUTE   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c BD Technologies   (United States)

^d LUDWIG INSTITUTE FOR CANCER RESEARCH   (Switzerland)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD8 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 100[209-2M]; HLA A2 ANTIGEN; IMMUNOLOGICAL ADJUVANT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONTANIDE ADJUVANT; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CLONAL ANERGY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CRYOPRESERVATION; CYTOKINE PRODUCTION; EFFECTOR CELL; EX VIVO STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNIZATION; IN VITRO STUDY; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; MELANOMA; MEMORY CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TREATMENT OUTCOME;

ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYTOKINES; DENDRITIC CELLS; DIMERIZATION; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON TYPE II; LEUKOCYTES, MONONUCLEAR; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM CIRCULATING CELLS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PEPTIDES; PHENOTYPE; T-LYMPHOCYTES;

EID: 10744231022     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0095-03     Document Type: Article

References (36)

1. Parkhurst, M. R., Salgaller, M. L., Southwood, S., Robbins, P. F., Sette, A., Rosenberg, S. A., and Kawakami, Y. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-a*0201-binding residues. J. Immunol., 157: 2539-2548, 1996.
2. Salgaller, M. L., Afshar, A., Marincola, F. M., Rivoltini, L., Kawakami, Y., and Rosenberg, S. A. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res., 55: 4972-4979, 1995.
3. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4: 321-327, 1998.
4. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Sznol, M., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Seipp, C. A., Einhorn, J. H., Rogers-Freezer, L., and White, D. E. Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine. J Immunol., 163: 1690-1695, 1999.
5. Lee, P., Wang, F., Kuniyoshi, J., Rubio, V., Stuges, T., Groshen, S., Gee, C., Lau, R., Jeffery, G., Margolin, K., Marty, V., and Weber, J. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol., 19: 3836-3847, 2001.
6. Lau, R., Wang, F., Jeffery, G., Marty, V., Kuniyoshi, J., Bade, E., Ryback, M. E., and Weber, J. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J. Immunother., 24: 66-78, 2001.
7. Nielsen, M. B., Monsurro, V., Migueles, S. A., Wang, E., Perez-Diez, A., Lee, K. H., Kammula, U., Rosenberg, S. A., and Marincola, F. M. Status of activation of circulating vaccine-elicited CD8+ T cells. J. Immunol., 165: 2287-2296, 2000.
8. Monsurro, V., Nagorsen, D., Wang, E., Provenzano, M., Dudley, M. E., Rosenberg, S. A., and Marincola, F. M. Functional heterogeneity of vaccine-induced CD8(+) T cells. J. Immunol., 168: 5933-5942, 2002.
9. Smith, J. W., Walker, E. B., Fox, B. A., Haley, D., Wisner, K. P., Doran, T., Fisher, B., Justice, L., Wood, W., Vetto, J., Maecker, H., Dols, A., Meijer, S., Hu, H. M., Romero, P., Alvord, W. G., and Urba, W. J. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J. Clin. Oncol., 21: 1562-1573, 2003.
10. Hu, H. M., Dols, A., Meijer, S. L., Floyd, K., Walker, E. B., Urba, W. J., and Fox, B. A. Immunological monitoring of melanoma patients following peptide vaccination using soluble peptide/HLA-A2 dimer complexes. J. Immunother., 27: 48-59, 2003.
11. Ismaili, J., Rennesson, J., Aksoy, E., Vekemans, J., Vincart, B., Amraoui, Z., Van Laethem, F., Goldman, M., and Dubois, P. M. Monophosphoryl lipid A activates both human dendritic cells and T cells. J. Immunol., 168: 926-932, 2002.
12. DiSanto, J. P., Terry, L. A., and Flomenberg, N. Generation of anti-human CD8 β-specific antibodies using transfectants expressing mixed-species CD8 heterodimers. J. Immunol. Methods, 141: 123-131, 1991.
13. Sallusto, F., Lenig, D., Forster, R., Lipp, M., and Lanzavecchia, A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature (Lond.), 401: 708-712, 1999.
14. Campbell, J. J., Murphy, K. E., Kunkel, E. J., Brightling, C. E., Soler, D., Shen, Z., Boisvert, J., Greenberg, H. B., Vierra, M. A., Goodman, S. B., Genovese, M. C., Wardlaw, A. J., Butcher, E. C., and Wu, L. CCR7 expression and memory T cell diversity in humans. J. Immunol., 166: 877-884, 2001.
15. Valmori, D., Scheibenbogen, C., Dutoit, V., Nagorsen, D., Asemissen, A. M., Rubio-Godoy, V., Rimoldi, D., Guillaume, P., Romero, P., Schadendorf, D., Lipp, M., Dietrich, P. Y., Thiel, E., Cerottini, J. C., Lienard, D., and Keilholz, U. Circulating tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity. Cancer Res., 62: 1743-1750, 2002.
16. Hamann, D., Baars, P. A., Rep, M. H., Hooibrink, B., Kerkhof-Garde, S. R., Klein, M. R., and van Lier, R. A. Phenotypic and functional separation of memory and effector human CD8+ T cells. J. Exp. Med., 186: 1407-1418, 1997.
17. Hamann, D., Kostense, S., Wolthers, K. C., Otto, S. A., Baars, P. A., Miedema, F., and van Lier, R. A. Evidence that human CD8+CD45RA+CD27- cells are induced by antigen and evolve through extensive rounds of division. Int. Immunol., 11: 1027-1033, 1999.
18. Champagne, P., Ogg, G. S., King, A. S., Knabenhans, C., Ellefsen, K., Nobile, M., Appay, V., Rizzardi, G. P., Fleury, S., Lipp, M., Forster, R., Rowland-Jones, S., Sekaly, R. P., McMichael, A. J., and Pantaleo, G. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature (Lond.), 410: 106-111, 2001.
19. Hazzan, M., Labalette, M., Noel, C., Lelievre, G., and Dessaint, J. P. Recall response to cytomegalovirus in allograft recipients: mobilization of CD57+, CD28+ cells before expansion of CD57+, CD28-cells within the CD8+ T lymphocyte compartment. Transplantation, 63: 693-698, 1997.
20. Hoflich, C., Docke, W. D., Busch, A., Kern, F., and Volk, H. D. CD45RA(bright)/CD11a(bright) CD8+ T cells: Effector T cells. Int. Immunol., 10: 1837-1845, 1998.
21. Yang, J., Lemas, V. M., Flinn, I. W., Krone, C., and Ambinder, R. F. Application of the ELISPOT assay to the characterization of CD8(+) responses to Epstein-Barr virus antigens. Blood, 95: 241-248, 2000.
22. Morse, M. A., Clay, T. M., Hobeika, A. C., Mosca, P. J., and Lyerly, H. K. Monitoring cellular immune responses to cancer immunotherapy. Curr. Opin. Mol. Ther., 3: 45-52, 2001.
23. Rooney, C. M., Smith, C. A., Ng, C. Y., Loftin, S. K., Sixbey, J. W., Gan, Y., Srivastava, D. K., Bowman, L. C., Krance, R. A., Brenner, M. K., and Heslop, H. E. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood, 92: 1549-1555, 1998.
24. Keilholz, U., Weber, J., Finke, J. H., Gabrilovich, D. I., Kast, W. M., Disis, M. L., Kirkwood, J. M., Scheibenbogen, C., Schlom, J., Maino, V. C., Lyerly, H. K., Lee, P. P., Storkus, W., Marincola, F., Worobec, A., and Atkins, M. B. Immunologic monitoring of cancer vaccine therapy: Results of a workshop sponsored by the society for biological therapy. J. Immunother., 25: 97-138, 2002.
25. Pittet, M. J., Speiser, D. E., Lienard, D., Valmori, D., Guillaume, P., Dutoit, V., Rimoldi, D., Lejeune, F., Cerottini, J. C., and Romero, P. Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide. Clin. Cancer Res., 7: 796s-803s, 2001.
26. Kaech, S. M., Wherry, E. J., and Ahmed, R. Effector and memory T-cell differentiation: Implications for vaccine development. Nat. Rev. Immunol., 2: 251-262, 2002.
27. Wherry, E. J., Puorro, K. A., Porgador, A., and Eisenlohr, L. C. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J. Immunol., 163: 3735-3745, 1999.
28. Kedl, R. M., Rees, W. A., Hildeman, D. A., Schaefer, B., Mitchell, T., Kappler, J., and Marrack, P. T cells compete for access to antigen-bearing antigen-presenting cells. J. Exp. Med., 192: 1105-1113, 2000.
29. Sun, J. C., and Bevan, M. J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science (Wash. DC), 300: 339-342, 2003.
30. Shedlock, D. J., and Shen, H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science (Wash. DC), 300: 337-339, 2003.
31. Aucouturier, J., Dupuis, L., Deville, S., Ascarateil, S, and Ganne, V. Montanide ISA 720 and 51: A new generation of water-in-oil emulsions adjuvants for human vaccines. Expert Rev. Vaccines, 1: 111-118, 2002.
32. Hioe, C. E., Qui, H., Chend, P. D., Bian, Z., Li, M. L., Li, J., Singh, M., Kuebler, P., McGee, P., O'Hagen, D., Zamb, T., Koff, W., Allsopp, C., Wang, C. Y., and Nixon, D. F. Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides. Vaccine, 14: 412-418, 1996.
33. Deliyannis, G., Jackson, D. C., Ede, N. J., Zeng, W., Hourdakis, I., Sakabetis, E., and Brown, L. E. Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J. Virol., 76: 4212-4221, 2002.
34. Stober, D., Jomantaite, I., Schirmbeck, R., and Reimann, J. NKT cells provide help for dendritic cell-dependent priming of MHC class I-restricted CD8+ T cells in vivo. J. Immunol., 170: 2540-2548, 2003.
35. Nishimura, T., Kitamura, H., Iwakabe, K., Yahata, T., Ohta, A., Sato, M., Takeda, K., Okumura, K., Van Kaer, L., Kawano, T., Taniguchi, M., Nakui, M., Sekimoto, M., and Koda, T. The interface between innate and acquired immunity: Glycolipid antigen presentation by CD1d-expressing dendritic cells to NKT cells induces the differentiation of antigen-specific cytotoxic T lymphocytes. Int. Immunol., 12: 987-994, 2000.
36. Fujii, S. I., Shimizu, K., Smith, C., Bonifaz, L., and Steinman, R. M. Activation of natural killer T cells by {α}-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein. J. Exp. Med., 198: 267-279, 2003.